MiCK
Correlation of the Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients
Sponsor study identifier
observational
300
2 countries
11
Study Start
December 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2012
Actual (reported)Study Completion
November 2012
Actual (reported)The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guiding chemotherapy of cancer patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2012
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2008
Date type not reportedThis date has not been verified as actual or estimated.
May 12, 2009
Actual (reported)May 13, 2009
Actual (reported)November 2012
Actual (reported)November 2012
Actual (reported)To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients, with emphasis on patients failing primary treatment, patients with unknown primary tumors, and patients with tumors difficult to treat such as carcinoma of lung.
one year
Correlate the MiCK assay results with objective response rates, symptom response rates, time to progression and survival of cancer patients treated with chemotherapy.
one year
Patients with pathological diagnoses of cancer or leukemia
3.1.3 Patients for whom chemotherapy is planned.
Cancer Patients for whom chemotherapy is planned.
Wilshire Oncology Medical Group, Inc
La Verne, California, 91750, United States
Tampa General Hospital
Tampa, Florida, 33606, United States
DiaTech Oncology
Brentwood, Tennessee, 37027, United States
Cumberland Medical Center
Crossville, Tennessee, 38555, United States
Middle Tennessee Medical Center
Murfreesboro, Tennessee, 37219, United States
Baptist Hospital
Nashville, Tennessee, 37203, United States
Nashville Oncology Associates
Nashville, Tennessee, 37203, United States
Bosserman L, Rogers K, Willis C, Davidson D, Whitworth P, Karimi M, Upadhyaya G, Rutledge J, Hallquist A, Perree M, Presant CA. Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancer. PLoS One. 2015 May 29;10(5):e0122609. doi: 10.1371/journal.pone.0122609. eCollection 2015.
Cary Presant, MD
Pierian Biosciences
Dirk Davidson, MD
Cumberland Medical Center
Karl Rogers, MD
Nashville Oncology Associates
Swapnil P. Rajurkar, MD
Wilshire Oncology Medical Group, Inc.
300 participants (actual enrollment reported by the registry).
First Submitted
May 12, 2009
First Posted
May 13, 2009
Study Start
December 2008
Date type not reportedThis date has not been verified as actual or estimated.
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Contact the study team to confirm eligibility.
St. Thomas Research Institute, LLC
Nashville, Tennessee, 37203, United States
Tennessee Breast Specialists
Nashville, Tennessee, 37203, United States
Tennessee Toracic Surgical Specialists
Nashville, Tennessee, 37205, United States
DiaTech Oncology
Montreal, Quebec, H2X 3P9, Canada
Laura Lawson, MD
Tennessee Breast Specialists
L. James Wudel Jr., MD
Tennessee Thoracic Surgical Specialists
Raymond F Bluth, MD
Baptist Hospital Nashville
Peter F Jelsma, MD
St. Thomas Research Institute, LLC
Richard D Michaelson, MD
Middle Tennessee Medical Center
Jorge E Marcet, MD
Tampa Gerneral Hospital
Primary Completion
November 2012
Actual (reported)Study Completion
November 2012
Actual (reported)Last Updated
November 14, 2012
Record last verified: 2012-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: